ImmunoGen, Inc. (IMGN)
Company Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer.
The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Country | United States |
Founded | 1980 |
IPO Date | Nov 16, 1989 |
Industry | Biotechnology |
Sector | Health Care |
Employees | 106 |
CEO | Mark Enyedy |
Contact Details
Address:
84 State St Boston, Massachusetts 02109-2202 United States | |
Phone | 781 895 0600 |
Website | immunogen.com |
Stock Details
Ticker Symbol | IMGN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | US Dollars |
CIK Code | 0000855654 |
CUSIP Number | 45253H101 |
ISIN Number | US45253H1014 |
Employer ID | 04-2726691 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Mark Joseph Enyedy | President, Chief Executive Officer and Director |
Susan Altschuller Ph.D. | Senior Vice President and Chief Financial Officer |
Dr. Anna Berkenblit M.D., MM.Sc | Senior Vice President and Chief Medical Officer |
Stacy A. Coen | Senior Vice President and Chief Business Officer |
Kristen Harrington-Smith | Senior Vice President and Chief Commercial Officer |
Renee Lentini | Vice President of Finance and Principal Accounting Officer |
Courtney O'Konek | Senior Director of Corporate Communications and Investor Relations |
Joseph J. Kenny | Vice President, Acting General Counsel, Intellectual Property and Secretary |
Audrey Bergan | Senior Vice President and Chief Human Resources Officer |
Dr. Theresa G. Wingrove | Senior Vice President of Regulatory Affairs and Quality |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 1, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
Aug 1, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
Aug 1, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
Jul 29, 2022 | 8-K | Current report |
Jul 5, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jul 5, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jul 5, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jul 5, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jul 5, 2022 | 4 | Statement of changes in beneficial ownership of securities |
Jul 5, 2022 | 4 | Statement of changes in beneficial ownership of securities |